Mohammed M. Milhem | University of Iowa ...

Dr. Mohammed Milhem, MBBS

Claim this profile

University of Iowa Hospitals and Clinics

Studies Melanoma
Studies Solid Tumors
18 reported clinical trials
32 drugs studied

Area of expertise

1Melanoma
Mohammed Milhem, MBBS has run 6 trials for Melanoma. Some of their research focus areas include:
Stage IV
BRAF positive
Stage III
2Solid Tumors
Mohammed Milhem, MBBS has run 3 trials for Solid Tumors. Some of their research focus areas include:
Stage IV
Stage III
Nectin-4 positive

Affiliated Hospitals

Image of trial facility.
University Of Iowa Hospitals And Clinics
Image of trial facility.
University Of Iowa

Clinical Trials Mohammed Milhem, MBBS is currently running

Image of trial facility.

TAB004 + Toripalimab

for Solid Cancers

The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004 monotherapy and in combination with toripalimab; and 3) determine the immunogenicity of TAB004 monotherapy and in combination with toripalimab and to determine the immunogenicity of toripalimab when administered with TAB004. The exploratory objectives are to: 1) evaluate pharmacodynamic effects of TAB004 on its target receptor BTLA, as well as effects on the immune system; 2) evaluate biomarkers that may correlate with activity of TAB004 as monotherapy and in combination with toripalimab; 3) evaluate the utility of BTLA ligand, herpesvirus-entry mediator (HVEM), and additional exploratory biomarkers that could aid in selection of appropriate subjects for TAB004 monotherapy and in combination with toripalimab.
Recruiting1 award Phase 110 criteria
Image of trial facility.

Multiple Targeted Therapies

for Meningioma

This trial studies four drugs to treat patients with worsening meningioma. These drugs work by blocking enzymes that the tumor cells need to grow. The trial focuses on patients whose tumors have specific genetic mutations.
Recruiting1 award Phase 210 criteria

More about Mohammed Milhem, MBBS

Clinical Trial Related1 year of experience running clinical trials · Led 18 trials as a Principal Investigator · 8 Active Clinical Trials
Treatments Mohammed Milhem, MBBS has experience with
  • Nivolumab
  • Temozolomide
  • Chlorpromazine
  • Radiation Therapy
  • Zoledronic Acid
  • Nicotinamide Riboside

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Mohammed Milhem, MBBS specialize in?
Is Mohammed Milhem, MBBS currently recruiting for clinical trials?
Are there any treatments that Mohammed Milhem, MBBS has studied deeply?
What is the best way to schedule an appointment with Mohammed Milhem, MBBS?
What is the office address of Mohammed Milhem, MBBS?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security